JP2013530237A5 - - Google Patents

Download PDF

Info

Publication number
JP2013530237A5
JP2013530237A5 JP2013518685A JP2013518685A JP2013530237A5 JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5 JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013518685 A JP2013518685 A JP 2013518685A JP 2013530237 A5 JP2013530237 A5 JP 2013530237A5
Authority
JP
Japan
Prior art keywords
group
salt
compound
following groups
following
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013518685A
Other languages
English (en)
Japanese (ja)
Other versions
JP5799479B2 (ja
JP2013530237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/042507 external-priority patent/WO2012006202A1/en
Publication of JP2013530237A publication Critical patent/JP2013530237A/ja
Publication of JP2013530237A5 publication Critical patent/JP2013530237A5/ja
Application granted granted Critical
Publication of JP5799479B2 publication Critical patent/JP5799479B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013518685A 2010-07-07 2011-06-30 Rhoキナーゼインヒビター Active JP5799479B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US36203610P 2010-07-07 2010-07-07
US61/362,036 2010-07-07
PCT/US2011/042507 WO2012006202A1 (en) 2010-07-07 2011-06-30 Rho kinase inhibitors

Publications (3)

Publication Number Publication Date
JP2013530237A JP2013530237A (ja) 2013-07-25
JP2013530237A5 true JP2013530237A5 (enExample) 2014-08-14
JP5799479B2 JP5799479B2 (ja) 2015-10-28

Family

ID=44514975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013518685A Active JP5799479B2 (ja) 2010-07-07 2011-06-30 Rhoキナーゼインヒビター

Country Status (4)

Country Link
US (1) US9079880B2 (enExample)
EP (1) EP2590942B1 (enExample)
JP (1) JP5799479B2 (enExample)
WO (1) WO2012006202A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012054367A1 (en) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
EA201500362A1 (ru) 2012-10-05 2015-08-31 Кадмон Корпорейшн, Ллк Ингибиторы rho-киназы
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
WO2016028971A1 (en) 2014-08-21 2016-02-25 Bristol-Myers Squibb Company Tied-back benzamide derivatives as potent rock inhibitors
US9353093B2 (en) 2014-10-07 2016-05-31 Allergan, Inc. Indole-1-carboxamides as kinase inhibitors
TW201706265A (zh) 2015-03-09 2017-02-16 必治妥美雅史谷比公司 做為Rho激酶(ROCK)抑制劑之內醯胺
CN109562106B (zh) 2016-06-21 2023-03-21 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) * 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
US10738007B2 (en) 2016-10-24 2020-08-11 Translation Drug Development, LLC Amide compounds as kinase inhibitors, compositions and methods of treatment
IL266150B2 (en) * 2016-10-24 2023-12-01 Translational Drug Dev Llc 3-substituted benzamide derivatives as kinase inhibitors
AU2020273376C1 (en) * 2016-10-24 2024-02-29 Translational Drug Development, Llc Amide compounds as kinase inhibitors, compositions and methods of treatment
GB201705686D0 (en) * 2017-04-07 2017-05-24 Centauri Therapeutics Ltd Novel compounds and therapeutic uses thereof
AU2018311976B2 (en) * 2017-08-04 2022-10-13 Takeda Pharmaceutical Company Limited Inhibitors of Plasma Kallikrein and uses thereof
JP7065951B2 (ja) 2017-09-22 2022-05-12 ジュビラント エピパッド エルエルシー Pad阻害剤としての複素環式化合物
WO2019077631A1 (en) 2017-10-18 2019-04-25 Jubilant Biosys Limited IMIDAZO-PYRIDINE COMPOUNDS FOR USE AS PAD INHIBITORS
EP3707135A1 (en) 2017-11-06 2020-09-16 Jubilant Prodel LLC Pyrimidine derivatives as inhibitors of pd1/pd-l1 activation
CN107903185B (zh) * 2017-11-08 2020-05-26 四川大学 新型eEF2K抑制剂的制备及应用
IL274762B2 (en) 2017-11-24 2023-10-01 Jubilant Episcribe Llc Novel heterocyclic compounds as prmt5 inhibitors
WO2019175897A1 (en) 2018-03-13 2019-09-19 Jubilant Biosys Limited Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation
EP3784226B1 (en) * 2018-04-24 2024-08-14 Translational Drug Development Llc Pyrazole-phenylamide derivatives as inhibitors of the rho-associated protein kinase rock1 and rock2 for the treatment of cancer
WO2020047229A1 (en) 2018-08-29 2020-03-05 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN119219603A (zh) * 2023-06-28 2024-12-31 科辉智药(深圳)新药研究中心有限公司 Sarm1酶活性抑制剂及其用途

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2516384B2 (ja) * 1987-11-27 1996-07-24 保土谷化学工業株式会社 ペンズアミド誘導体
US5210208A (en) 1990-09-24 1993-05-11 Rhone-Poulenc Rorer Pharmaceuticals Inc. Disubstituted aryl compounds exhibiting selective leukotriene b4 antagonist activity
NZ240863A (en) 1991-09-11 1995-04-27 Mcneilab Inc Substituted 4-aryl piperidine and 4-aryl piperazine derivatives, preparation and pharmaceutical compositions thereof
JPH11130751A (ja) 1997-10-30 1999-05-18 Yoshitomi Pharmaceut Ind Ltd アミド化合物およびそれらの酸付加塩の標識化合物
US7217722B2 (en) 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
WO2002044126A2 (en) 2000-11-28 2002-06-06 Guilford Pharmaceuticals Inc. Bisubstituted carbocyclic cyclophilin binding compounds and theirus
DE10112768A1 (de) 2001-03-16 2002-09-19 Merck Patent Gmbh Phenylderivate 3
WO2002100833A1 (en) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Rho KINASE INHIBITORS
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20040186151A1 (en) 2003-02-12 2004-09-23 Mjalli Adnan M.M. Substituted azole derivatives as therapeutic agents
FR2862965B1 (fr) 2003-11-27 2007-09-07 Merck Sante Sas Nouveaux derives de phenoxyacetamides et leur utilisation pour la preparation de diphenylamides.
MX2007003332A (es) 2004-09-20 2007-06-05 Xenon Pharmaceuticals Inc Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
WO2006052542A2 (en) 2004-11-04 2006-05-18 Neurogen Corporation Arylalkyl ureas as cb1 antagonists
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
JP5235887B2 (ja) 2006-09-20 2013-07-10 アエリー ファーマシューティカルズ インコーポレイテッド Rhoキナーゼ阻害剤
WO2008053319A1 (en) 2006-10-30 2008-05-08 Pfizer Products Inc. Amide resorcinol compounds
EP2079694B1 (en) 2006-12-28 2017-03-01 Rigel Pharmaceuticals, Inc. N-substituted-heterocycloalkyloxybenzamide compounds and methods of use
CL2007003874A1 (es) 2007-01-03 2008-05-16 Boehringer Ingelheim Int Compuestos derivados de benzamida; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades cardiovasculares, hipertension, aterosclerosis, reestenosis, ictus, insuficiencia cardiaca, lesion isquemica, hipertensio
WO2008157330A1 (en) 2007-06-14 2008-12-24 Smithkline Beecham Corporation Chemical compounds
EP2193119B1 (en) 2007-08-27 2014-01-01 Abbvie Deutschland GmbH & Co. KG 4-(4-pyridinyl)-benzamides and their use as rock activity modulators
EP2194045A4 (en) 2007-08-30 2011-09-21 Takeda Pharmaceutical Substituted pyrazole derivative
MX2010005298A (es) 2007-11-16 2010-06-30 Rigel Pharmaceuticals Inc Compuestos de carboxamida, sulfonamida y amina para trastornos metabolicos.
TW200944506A (en) 2008-03-26 2009-11-01 Takeda Pharmaceutical Substituted pyrazole derivatives and use thereof
US8697911B2 (en) 2010-07-07 2014-04-15 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
US9079880B2 (en) 2010-07-07 2015-07-14 Boehringer Ingelheim International Gmbh Rho kinase inhibitors
WO2012054367A1 (en) 2010-10-19 2012-04-26 Boehringer Ingelheim International Gmbh Rho kinase inhibitors

Similar Documents

Publication Publication Date Title
JP2013530237A5 (enExample)
JP2013531013A5 (enExample)
JP2013544797A5 (enExample)
RU2012103487A (ru) Ингибирующие jak соединения на основе пиразолопиримидина и способы
JP2019520396A5 (enExample)
JP2014533259A5 (enExample)
JP2019518766A5 (enExample)
JP2017071634A5 (enExample)
JP2016510032A5 (enExample)
JP2019517475A5 (enExample)
JP2016510033A5 (enExample)
ES2732902T3 (es) Bencimidazol-2-aminas como inhibidores de MIDH1
JP2019520402A5 (enExample)
JP2009502830A5 (enExample)
TN2018000130A1 (en) N-[2-(1 -benzylpiperidin-4-yl)ethyl]-4-(pyrazin-2-yl)-piperazine-1 -carboxamide derivatives and related compounds as muscarinic receptor 4 (m4) antagonists for treating neurological diseases
JP2018501285A5 (enExample)
JP2018507877A5 (enExample)
JP2014521653A5 (enExample)
JP2010529134A5 (enExample)
JP2014514360A5 (enExample)
JP2016505042A5 (enExample)
JP2015510942A5 (enExample)
JP2017511794A5 (enExample)
KR102493943B1 (ko) 포유류 티로신 키나제 ROR1 활성의 저해제로서 유용한 2-페닐-3H-이미다조[4,5-b]피리딘 유도체
JP2012505234A5 (enExample)